Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseWilliam J. Sandborn, Asit Parikh, Jing Xu et al.|New England Journal of Medicine|2013Cited by 2.7k
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment FailedBruce E. Sands, Stephen B. Hanauer, Brian G. Feagan et al.|Gastroenterology|2014Cited by 714
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's diseaseMaria Rosario, Irving H. Fox, Nathanael L. Dirks et al.|Alimentary Pharmacology & Therapeutics|2015Cited by 266
Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s DiseaseMaria Rosario, Irving H. Fox, Jonathan French et al.|Journal of Crohn s and Colitis|2017Cited by 161
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of VedolizumabMaria Rosario, Irving H. Fox, Nathanael L. Dirks et al.|Clinical Pharmacokinetics|2017Cited by 158